Industries > Pharma > Global Allergic Rhinitis Drugs Market 2018-2028

Global Allergic Rhinitis Drugs Market 2018-2028

Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines

PUBLISHED: 24 August 2018
PAGES: 256
PRODUCT CODE: PHA0328

Clear
WOOCS 2.2.1
SKU: PHA0328 Categories: , , Tag:

The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.3% in the first half of the forecast period. The market is estimated at $12.2bn in 2017 and $14.3bn in 2022.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 256-page report you will receive 97 tables and 100 figures– all unavailable elsewhere.

The 256-page report provides clear detailed insight into the global allergic rhinitis drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Allergic Rhinitis Drugs Market forecasts from 2018-2028

• Along with revenue prediction for the overall world market for allergic rhinitis drugs, our investigation shows forecasts to 2028 for the following submarkets:
• Intranasal Antihistamines
• Intranasal Corticosteroids
• Oral Antihistamines
• Immunotherapy and Vaccines

Global Allergic Rhinitis Drugs Market 2018-2028

• How will leading allergic rhinitis drugs perform to 2028 at world level? Our study forecasts individual revenues of these 27 products:
• Patanase
• Astepro
• Astelin
• Dymista
• Nasonex
• Avamys
• Veramyst
• Flixonase
• Rhinocort
• Omnaris
• Nasacort
• Beconase
• Qnasl
• Zetonna
• Allegra
• Zyrtec
• Claritin
• Xyzal
• Allelock
• Clarinex
• Ebastel
• Talion
• Staloral
• Alutard SQ
• Grazax
• Ragwitek
• Generic Azelastine

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• US
• EU5 – Germany, UK, France, Italy and Spain
• China
• Japan
• India
• Russia
• Brazil
• Rest of the World

Each national market is further segmented by submarket.

• Our work provides analysis and sales forecast of the leading companies in the allergic rhinitis drugs market:
• GlaxoSmithKline (GSK)
• Merck & Co
• Sanofi
• Johnson & Johnson
• ALK-Abello
• UCB
• Kyowo Hako Kirin
• Stallergenes Greer

• This report discusses the trends and development in the allergic rhinitis pipeline

• Our study discusses strengths, weaknesses, opportunities and threats as well as porter’s five forces analysis of the global allergic rhinitis drugs market

Visiongain’s study is intended for anyone requiring commercial analyses for the global allergic rhinitis drugs market. You find data, trends and predictions.

Buy our report today Allergic Rhinitis Drugs Market Forecast : Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Allergic Rhinitis Drugs Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Allergic Rhinitis Drugs Market 2018-2028


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories